Recombinant Anti-CD64 x Anti-malaria antigen Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD64 antibody variable domain is fused to CH1 and the other scFv from an anti-malaria antigen antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget NK cells to genus plasmodium. It is designed for the research of Malaria therapy.